[
  {
    "abstract_id": "ENDO-2026-OR-12-1",
    "title": "Bivamelagon MC4R agonist in obesity — Phase 2 dose-ranging (synthetic)",
    "authors": "Mock AI, Mock AJ",
    "abstract_text": "Bivamelagon (LB54640), an oral MC4R agonist, demonstrated -7.3% placebo-adjusted weight loss at 14 weeks in a synthetic Phase 2 obesity cohort. GI AE 10.5%. Mock data.",
    "phase": "Phase 2",
    "weight_loss_pct": 7.3,
    "gi_ae_pct": 10.5
  },
  {
    "abstract_id": "ENDO-2026-OR-12-2",
    "title": "HM15211 (efocipegtrutide) GLP-1/GIP/glucagon triple in MASH-obesity — Phase 2 (mock)",
    "authors": "Mock AK",
    "abstract_text": "HM15211 (efocipegtrutide) achieved -10.9% placebo-adjusted weight loss at 32 weeks in a synthetic Phase 2 MASH-obesity cohort. GI AE 24.6%. Mock data.",
    "phase": "Phase 2",
    "weight_loss_pct": 10.9,
    "gi_ae_pct": 24.6
  },
  {
    "abstract_id": "ENDO-2026-PO-134",
    "title": "TERN-601 oral GLP-1 small molecule — Phase 1b in obesity (mock)",
    "authors": "Mock AL, Mock AM",
    "abstract_text": "TERN-601 oral GLP-1 RA achieved -4.9% placebo-adjusted weight loss at 4 weeks in a Phase 1b synthetic obesity cohort. GI AE 14.0%. Mock dataset.",
    "phase": "Phase 1b",
    "weight_loss_pct": 4.9,
    "gi_ae_pct": 14.0
  },
  {
    "abstract_id": "ENDO-2026-PO-141",
    "title": "MET-097i monthly subcutaneous GLP-1 — Phase 1 first-in-human (synthetic)",
    "authors": "Mock AN",
    "abstract_text": "MET-097i, a monthly subcutaneous GLP-1 RA from Metsera, achieved -7.5% mean weight loss at 12 weeks in synthetic Phase 1 obesity cohort. GI AE 16.8%. Mock data.",
    "phase": "Phase 1",
    "weight_loss_pct": 7.5,
    "gi_ae_pct": 16.8
  },
  {
    "abstract_id": "ENDO-2026-PO-150",
    "title": "DA-1726 GLP-1/glucagon dual — Phase 1 multiple ascending dose (mock)",
    "authors": "Mock AO",
    "abstract_text": "DA-1726 (NeuroBo / Dong-A) demonstrated -4.3% placebo-adjusted weight loss at 4 weeks in a synthetic Phase 1 MAD obesity cohort. GI AE 12.2%. Mock data.",
    "phase": "Phase 1",
    "weight_loss_pct": 4.3,
    "gi_ae_pct": 12.2
  }
]